Premium
Organon & Co (7XP)
TG
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-06 | Holzbaur LynetteSenior VP of Finance & Corporate Controller | -26,45k | 353,08k | Vente | 13,35 | 0,00 | -100,00% |
| 2026-03-31 | Ms. Juliana Papa DrinaneHead of Manufacturing & Supply | 10,82k | 0,00 | Derivative Exercise and Retained Stock | - | 33,24k | 48,24% |
| 2026-03-31 | Ms. Juliana Papa DrinaneHead of Manufacturing & Supply | -5,64k | 32,13k | Derivative Exercise and Sale | 5,70 | 33,24k | - |
| 2026-03-31 | Dr. Juan Camilo Arjona FerreiraExec. VP, Head of Research & Development and Chief Medical Officer | -4,82k | 27,47k | Derivative Exercise and Sale | 5,70 | 30,05k | - |
| 2026-03-31 | Dr. Juan Camilo Arjona FerreiraExec. VP, Head of Research & Development and Chief Medical Officer | 8,61k | 0,00 | Derivative Exercise and Retained Stock | - | 30,05k | 40,17% |
| 2026-03-31 | Mr. Daniel KarpChief Strategy Officer & Head of Corporate Development | -5,66k | 32,26k | Derivative Exercise and Sale | 5,70 | 69,55k | - |
| 2026-03-31 | Mr. Daniel KarpChief Strategy Officer & Head of Corporate Development | 12,39k | 0,00 | Derivative Exercise and Retained Stock | - | 69,55k | 21,69% |
| 2026-03-31 | Ms. Rachel A. StahlerExec. VP, Chief Information Officer and Chief Digital & Growth Officer | 12,40k | 0,00 | Derivative Exercise and Retained Stock | - | 116,11k | 11,96% |
| 2026-03-31 | Ms. Rachel A. StahlerExec. VP, Chief Information Officer and Chief Digital & Growth Officer | -6,46k | 36,84k | Derivative Exercise and Sale | 5,70 | 116,11k | - |
| 2026-03-31 | Mr. Matthew M. WalshExec. VP & CFO | 22,09k | 0,00 | Derivative Exercise and Retained Stock | - | 212,75k | 11,58% |
| 2026-03-31 | Mr. Matthew M. WalshExec. VP & CFO | -11,51k | 65,59k | Derivative Exercise and Sale | 5,70 | 212,75k | - |
| 2026-03-31 | Mr. Aaron FalcioneExec. VP & Chief HR Officer | -6,14k | 35,00k | Derivative Exercise and Sale | 5,70 | 101,43k | - |
| 2026-03-31 | Mr. Aaron FalcioneExec. VP & Chief HR Officer | 11,79k | 0,00 | Derivative Exercise and Retained Stock | - | 101,43k | 13,15% |
| 2026-03-31 | Mr. Kirke WeaverExec. VP, General Counsel & Corporate Secretary | 13,24k | 0,00 | Derivative Exercise and Retained Stock | - | 92,64k | 16,67% |
| 2026-03-31 | Mr. Kirke WeaverExec. VP, General Counsel & Corporate Secretary | -5,28k | 30,07k | Derivative Exercise and Sale | 5,70 | 92,64k | - |
| 2026-03-31 | Mr. Vittorio NisitaExec. VP and Head of Enterprise Services & Solutions | 8,55k | 0,00 | Derivative Exercise and Retained Stock | - | 70,62k | 13,77% |
| 2026-03-31 | Mr. Vittorio NisitaExec. VP and Head of Enterprise Services & Solutions | -4,45k | 25,38k | Derivative Exercise and Sale | 5,70 | 70,62k | - |
| 2026-03-31 | Holzbaur LynetteSenior VP of Finance & Corporate Controller | 7,84k | 0,00 | Derivative Exercise and Retained Stock | - | 26,40k | 42,24% |
| 2026-03-31 | Holzbaur LynetteSenior VP of Finance & Corporate Controller | -3,13k | 17,82k | Derivative Exercise and Sale | 5,70 | 26,40k | - |
| 2026-03-31 | Mr. Joseph T. MorrisseyCEO | 17,58k | 0,00 | Derivative Exercise and Retained Stock | - | 123,12k | 16,66% |
| 2026-03-31 | Mr. Joseph T. MorrisseyCEO | -7,01k | 39,93k | Derivative Exercise and Sale | 5,70 | 123,12k | - |
| 2026-03-29 | Ms. Rachel A. StahlerExec. VP, Chief Information Officer and Chief Digital & Growth Officer | 5,39k | 0,00 | Derivative Exercise and Retained Stock | - | 103,70k | 5,48% |
| 2026-03-29 | Ms. Rachel A. StahlerExec. VP, Chief Information Officer and Chief Digital & Growth Officer | -2,81k | 16,40k | Derivative Exercise and Sale | 5,84 | 103,70k | - |
| 2026-03-29 | Holzbaur LynetteSenior VP of Finance & Corporate Controller | -1,52k | 8,85k | Derivative Exercise and Sale | 5,84 | 18,56k | - |
| 2026-03-29 | Holzbaur LynetteSenior VP of Finance & Corporate Controller | 3,80k | 0,00 | Derivative Exercise and Retained Stock | - | 18,56k | 25,77% |
| 2026-03-29 | Mr. Daniel KarpChief Strategy Officer & Head of Corporate Development | -4,45k | 25,96k | Derivative Exercise and Sale | 5,84 | 57,15k | - |
| 2026-03-29 | Mr. Daniel KarpChief Strategy Officer & Head of Corporate Development | 9,74k | 0,00 | Derivative Exercise and Retained Stock | - | 57,15k | 20,54% |
| 2026-03-29 | Mr. Kirke WeaverExec. VP, General Counsel & Corporate Secretary | 5,55k | 0,00 | Derivative Exercise and Retained Stock | - | 79,40k | 7,51% |
| 2026-03-29 | Mr. Kirke WeaverExec. VP, General Counsel & Corporate Secretary | -2,21k | 12,91k | Derivative Exercise and Sale | 5,84 | 79,40k | - |
| 2026-03-29 | Mr. Vittorio NisitaExec. VP and Head of Enterprise Services & Solutions | 3,79k | 0,00 | Derivative Exercise and Retained Stock | - | 62,07k | 6,50% |
| 2026-03-29 | Mr. Vittorio NisitaExec. VP and Head of Enterprise Services & Solutions | -1,97k | 11,53k | Derivative Exercise and Sale | 5,84 | 62,07k | - |
| 2026-03-29 | Ms. Juliana Papa DrinaneHead of Manufacturing & Supply | 5,25k | 0,00 | Derivative Exercise and Retained Stock | - | 22,42k | 30,54% |
| 2026-03-29 | Ms. Juliana Papa DrinaneHead of Manufacturing & Supply | -2,73k | 15,96k | Derivative Exercise and Sale | 5,84 | 22,42k | - |
| 2026-03-29 | Dr. Juan Camilo Arjona FerreiraExec. VP, Head of Research & Development and Chief Medical Officer | -3,18k | 18,58k | Derivative Exercise and Sale | 5,84 | 21,44k | - |
| 2026-03-29 | Dr. Juan Camilo Arjona FerreiraExec. VP, Head of Research & Development and Chief Medical Officer | 5,68k | 0,00 | Derivative Exercise and Retained Stock | - | 21,44k | 36,08% |
| 2026-03-29 | Mr. Aaron FalcioneExec. VP & Chief HR Officer | 5,54k | 0,00 | Derivative Exercise and Retained Stock | - | 89,65k | 6,58% |
| 2026-03-29 | Mr. Aaron FalcioneExec. VP & Chief HR Officer | -2,89k | 16,85k | Derivative Exercise and Sale | 5,84 | 89,65k | - |
| 2026-03-29 | Mr. Matthew M. WalshExec. VP & CFO | 9,91k | 0,00 | Derivative Exercise and Retained Stock | - | 190,66k | 5,48% |
| 2026-03-29 | Mr. Matthew M. WalshExec. VP & CFO | -5,16k | 30,15k | Derivative Exercise and Sale | 5,84 | 190,66k | - |
| 2026-03-29 | Mr. Joseph T. MorrisseyCEO | 6,97k | 0,00 | Derivative Exercise and Retained Stock | - | 105,54k | 7,07% |
| 2026-03-29 | Mr. Joseph T. MorrisseyCEO | -2,78k | 16,23k | Derivative Exercise and Sale | 5,84 | 105,54k | - |
| 2026-02-27 | Mr. Aaron FalcioneExec. VP & Chief HR Officer | -11,01k | 79,05k | Sale to Issuer | 7,17 - 7,23 | 84,11k | -11,57% |
| 2026-02-27 | Mr. Matthew M. WalshExec. VP & CFO | -19,00k | 136,51k | Sale to Issuer | 7,17 - 7,23 | 180,75k | -9,51% |
| 2026-02-27 | Mr. Vittorio NisitaExec. VP and Head of Enterprise Services & Solutions | -7,79k | 55,91k | Sale to Issuer | 7,17 - 7,23 | 58,28k | -11,78% |
| 2026-02-27 | Ms. Rachel A. StahlerExec. VP, Chief Information Officer and Chief Digital & Growth Officer | -10,72k | 76,96k | Sale to Issuer | 7,17 - 7,23 | 98,31k | -9,83% |
| 2026-02-27 | Mr. Kirke WeaverExec. VP, General Counsel & Corporate Secretary | -8,58k | 61,61k | Sale to Issuer | 7,17 - 7,23 | 73,85k | -10,41% |
| 2026-02-27 | Mr. Joseph T. MorrisseyCEO | -10,27k | 73,77k | Sale to Issuer | 7,17 - 7,23 | 98,57k | -9,44% |
| 2025-11-07 | Ms. Juliana Papa DrinaneHead of Manufacturing & Supply | -1,24k | 8,33k | Sale to Issuer | 6,71 | 17,18k | -6,74% |
| 2025-11-12 | Ms. Carrie Smith CoxExecutive Chair of the Board | 65,40k | 501,76k | Achat | 7,67 | 77,87k | 524,50% |
| 2025-11-07 | Ms. Juliana Papa DrinaneHead of Manufacturing & Supply | 3,63k | 0,00 | Derivative Exercise and Retained Stock | - | 17,18k | 26,76% |
| 2025-11-07 | Dr. Juan Camilo Arjona FerreiraExec. VP, Head of Research & Development and Chief Medical Officer | 4,14k | 0,00 | Derivative Exercise and Retained Stock | - | 28,92k | 16,71% |
| 2025-11-07 | Dr. Juan Camilo Arjona FerreiraExec. VP, Head of Research & Development and Chief Medical Officer | -2,31k | 15,48k | Derivative Exercise and Sale | 6,71 | 28,92k | - |
| 2025-11-07 | Holzbaur LynetteSenior VP of Finance & Corporate Controller | 1,73k | 0,00 | Derivative Exercise and Retained Stock | - | 14,68k | 13,35% |
| 2025-11-07 | Holzbaur LynetteSenior VP of Finance & Corporate Controller | -689,00 | 4,62k | Derivative Exercise and Sale | 6,71 | 14,68k | - |
| 2025-11-05 | Holzbaur LynetteSenior VP of Finance & Corporate Controller | 2,17k | 0,00 | Derivative Exercise and Retained Stock | - | 12,95k | 20,14% |
| 2025-11-05 | Holzbaur LynetteSenior VP of Finance & Corporate Controller | -866,00 | 5,65k | Derivative Exercise and Sale | 6,52 | 12,95k | - |
| 2025-08-11 | Dr. Juan Camilo Arjona FerreiraExec. VP, Head of Research & Development and Chief Medical Officer | 7,40k | 0,00 | Derivative Exercise and Retained Stock | - | 24,78k | 42,56% |
| 2025-08-11 | Dr. Juan Camilo Arjona FerreiraExec. VP, Head of Research & Development and Chief Medical Officer | -4,12k | 38,00k | Derivative Exercise and Sale | 9,22 | 24,78k | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
